BUY RBL Bank

Higher NPAs, Opex dent earnings

BFSI - Banks > Result Update > October 20, 2024

RBL posted a miss in earnings (~33%) with PAT at Rs2.2bn/0.6% RoA, mainly due to dip in NIM to ~5%, higher staff cost (owing to pay hikes and ~800-900 in-house collection fleet added in Q2), and LLP (led by higher slippages in CC + MFI book). Credit growth also moderated to 15% YoY due to the bank's strategy to prune its low-yielding corporate book and slowdown in unsecured loan growth (including Cards and MFI); however, the bank remains focused on building its high yielding secured retail/SME book for better RaRoC. GNPA ratio inched-up QoQ to 2.9% due to transitional pain in the BAF-RBL card portfolio (as the bank took charge of collection) and MFI book (mainly in Bihar). Bank expects asset quality pain to ease over the next 6M. We trim our estimates for FY25-27 factoring in higher staff cost and LLP, but retain BUY with TP of Rs325 (valuing the bank at 1.1x Sep-26E ABV). Current valuations remain inexpensive at 0.7x Sep-26E ABV. We recommend RBL for investors ready to trade near-term pain for long-term gain as the ongoing transformation should result in a sustained RoA of >1%.

RBL Bank: Financial Snapshot (Standalone)											
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E						
Net profit	8,756	11,679	12,246	16,496	25,013						
Loan growth (%)	17.0	19.6	15.3	17.9	19.9						
NII growth (%)	24.1	20.9	13.2	18.5	19.6						
NIM (%)	4.9	5.2	5.0	5.1	5.2						
PPOP growth (%)	(20.0)	38.1	24.6	31.9	31.6						
Adj. EPS (Rs)	14.6	19.4	20.2	27.1	41.2						
Adj. EPS growth (%)	0.0	32.8	4.2	34.4	51.6						
Adj. BV (Rs)	216.8	237.9	254.2	274.7	308.8						
Adj. BVPS growth (%)	(5.4)	8.0	9.8	6.8	8.1						
RoA (%)	0.8	0.9	0.8	1.0	1.2						
RoE (%)	6.7	8.2	8.0	9.9	13.5						
P/E (x)	14.1	10.6	10.2	7.6	5.0						
P/ABV (x)	0.9	0.9	0.8	0.7	0.7						

Source: Company, Emkay Research

Focus remains on building secured retail +SME book for sustained healthy RaRoC

Overall credit growth moderated for yet another quarter to 15% YoY/1.4% QoQ, primarily due to contraction in its low-yielding corporate book and deliberate slowdown in unsecured loan growth – mainly cards and MFI. New cards addition declined QoQ (~5.2mn–CIF vs 5.3mn in Q1), possibly due to rising stress in unsecured loans and the bank's strategy to reduce dependence on sourcing from BAF. MFI growth also has been on the back foot due to seasonal factors and rising stress in select states. On the other hand, deposit growth remains healthy at 20% YoY/6.5% QoQ, with CASA ratio increasing by ~100bps QoQ to 33.6%. However, higher slippages and lower disbursals in MFI, coupled with the absence of a one-off IT refund income in Q1 and interest reversal on NPAs, led to contraction in NIMs to ~5% (vs 5.7% in Q1). The bank reiterated its stance to reduce the share of Card + MFI from the current 32% to 25% over the years, mostly by higher growth in SME and the secured retail book (including mortgages, gold loans, and rural VF) to deliver sustained, healthy RaRoC.

Elevated stress in cards + MFI remains an irritant

Gross slippages remained elevated at Rs10.3bn/4.7% of loans, given rising stress in its cards portfolio (mainly due to transition of collection from BAF to bank) and industrywide stress in the MFI book. Stress in non-BAF card remains well-contained and the bank remains hopeful of normalcy in the BAF-RBL Card portfolio soon. MFI collection efficiency declined in Sep-24 to 97.5% (vs ~99% levels in previous months) mainly due to flood-related issues in Bihar (30% portfolio share) and other states like Rajasthan, Punjab, Haryana, and Jharkhand. This, should normalize as the impact of floods in Bihar recede. The bank continues to hold contingent provision buffer for its cards + MFI + PL portfolio, apart from healthy specific PCR at >70%. The RBI has yet not instructed the bank to increase risk weights on its MFI portfolio, impact of which could otherwise be 40bps.

We retain BUY on RBL with TP of Rs325

We trim our earnings for FY25-27E factoring in higher staff cost (partly offset by lower vendor payout as collection shifts to bank) and LLP, but retain BUY (TP of Rs325 valuing the bank at 1.1x Sep-26E ABV) given inexpensive valuations at 0.7x Sep-26E ABV. We recommend RBL for investors ready to trade near-term pain for long-term gain as the ongoing transformation should result in a sustained RoA of >1%.



Ticker

TARGET PRICE (Rs): 325

Target Price – 12M	Sep-25
Change in TP (%)	-
Current Reco.	BUY
Previous Reco.	BUY
Upside/(Downside) (%)	58.3
CMP (18-Oct-24) (Rs)	205.3

Stock Data

I

(

301
190
607.7
125
1,484
NA
9
1,931.3
23.0
99.0
24,854
84.1
-
14.6/27.0

Mathematical System Mathematical System

1-Year share price trend (Rs)



Anand Dama

anand.dama@emkayglobal.com +91 22 6624 2480

Nikhil Vaishnav

nikhil.vaishnav@emkayglobal.com +91 22 6624 2485

Kunaal N

kunaal.n@emkayglobal.com +91 22 6612 1275


Marazbaan Dastur

marazbaan.dastur@emkayglobal.com +91 22 6612 1281

This report is intended for gaurav.narkar@emkayglobal.com use and downloaded at 10/21/2024 11:31 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAYsGO>Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.


Story in Charts

Exhibit 1: Credit growth sees moderation yet again, but deposit growth remains strong...




Source: Company, Emkay Research

Exhibit 3: NIMs contract in absence of one-off interest on IT refund




Source: Company, Emkay Research

Exhibit 5: Transition impacted credit costs in BFL Co-branded Cards portfolio...




Source: Company, Emkay Research

Exhibit 2: ...primarily due to contraction in CB and unsecured book; however, secured retail growth remains healthy




Source: Company, Emkay Research

Exhibit 4: NPAs remain elevated, given the elevated stress from the card book and MFI segment



Source: Company, Emkay Research


Exhibit 6: ...while BFL Co-brand's early bucket collection efficiency are trending to pre-transition levels



Source: Company, Emkay Research


This report is intended for gauray narkar @emkayolobal.com use and downloaded at 10/21/2024 11:31 AM Emkay Research is also available on www.emkayolobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Exhibit 7: Collection efficiency of MFI book has dropped mainly due to stress seen in select states



Source: Company, Emkay Research

Exhibit 9: We expect the bank's RoA to remain <1% in FY25E due to higher staff cost/LLP, but gradually improve on account of better risk-adjusted margins and lower LLP



Source: Company, Emkay Research


Exhibit 11: Actuals vs Estimates (Q2FY25)

(Rs mn)	Actuals	Estin	nates	Varia	ation	Comments
(K3 IIII)	Actuals	Emkay	Consensus	Emkay	Consensus	
Net income	25,423	24,850	25,305	2%	0%	Higher other income led to a beat
PPOP	9,098	8,712	8,930	4%	2%	Higher staff cost offset by lower other opex led to a beat
PAT	2,225	3,327	3,077	-33%	-28%	Higher LLP due to stress in cards and MFI book led to a major miss

Source: Company, Emkay Research

Product-wise GNPA (%)

Exhibit 8: Cards, MFI portfolio exhibit higher stress levels







Exhibit 10: The stock currently trades at reasonable valuations



Source: Company, Emkay Research

Exhibit 12: Quarterly summary (Q2FY25)

(Rs mn)	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	YoY (%)	QoQ (%)	FY24A	FY25E	YoY (%)
Interest Earned	30,080	31,914	33,391	34,962	35,309	17	1	123,943	144,773	17
Interest Exp	15,330	16,455	17,392	17,963	19,160	25	7	63,514	76,357	20
Net Interest Income	14,750	15,459	15,999	17,000	16,150	9	-5	60,429	68,416	13
Global NIMs (reported)	5.54	5.52	5.45	5.67	5.04	-50bps	-63bps	5.16	5.00	-16bps
Non-interest Income	7,044	7,776	8,755	8,055	9,274	32	15	30,429	37,523	23
Operating Expenses	14,484	15,582	15,883	16,464	16,325	13	-1	60,550	68,177	13
Pre Provisioning Profit	7,310	7,653	8,870	8,591	9,098	24	6	30,307	37,762	25
Provision & Contingencies	6,404	4,581	4,138	3,663	6,183	-3	69	17,785	21,649	22
PBT	906	3,071	4,732	4,928	2,915	222	-41	12,523	16,113	29
Income Tax Expense (Gain)	-2,035	740	1,206	1,213	690	-134	-43	844	3,867	358
Net Profit/(Loss)	2,941	2,331	3,526	3,715	2,225	-24	-40	11,679	12,246	5
Gross NPA (%)	3.12	3.12	2.65	2.69	2.87	-25bps	19bps	2.65	2.84	19bps
Net NPA (%)	0.78	0.80	0.74	0.74	0.79	1bps	6bps	0.74	0.78	5bps
Deposits (Rs bn)	898	927	1,035	1,014	1,080	20	7	1,035	1,234	19
Net Advances (Rs bn)	763	799	840	867	879	15	1	840	969	15

Source: Company, Emkay Research

Exhibit 13: Revision in estimates

Y/E Mar (Rs mn)		FY25E			FY26E			FY27E	
	Earlier	Revised	Change	Earlier	Revised	Change	Earlier	Revised	Change
Net income	105,928	105,939	0.0%	105,928	105,939	0.0%	151,142	152,674	1.0%
PPOP	38,948	37,762	-3.0%	38,948	37,762	-3.0%	65,838	65,541	-0.5%
PAT	14,930	12,246	-18.0%	14,930	12,246	-18.0%	26,613	25,013	-6.0%
EPS (Rs)	24.7	20.2	-18.1%	24.7	20.2	-18.1%	43.9	41.2	-6.3%
BV (Rs)	268.3	263.5	-1.8%	268.3	263.5	-1.8%	337.9	324.8	-3.9%

Source: Emkay Research

Exhibit 14: Key Assumptio	ns			
(%)	FY24A	FY25E	FY26E	FY27E
Loan Growth	19.6	15.3	17.9	19.9
Deposit Growth	21.9	19.2	20.1	21.4
NIM	5.2	5.0	5.1	5.2
GNPA	2.7	2.8	3.0	3.1
Credit Cost	1.8	2.5	2.1	2.4

Source: Emkay Research

This report is intended for gauray narkar@emkayolobal.com use and downloaded at 10/21/2024 11:31 AM Emkay Research is also available on www.emkayolobal.com and Bloomberg EMKAY-GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Exhibit 15: Ratios and Trends

	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25
Loans (Rs mn)	629,417	666,840	702,094	730,870	763,242	799,490	839,869	867,040	878,823
Loans YoY (%)	12.4	14.7	17.0	21.3	21.3	19.9	19.6	18.6	15.1
Loans QoQ (%)	4.4	5.9	5.3	4.1	4.4	4.7	5.1	3.2	1.4
Liability Profile (%)									
CASA	36.2	36.6	37.3	37.3	35.7	33.8	35.2	32.6	33.6
CA	14.8	15.7	17.4	17.7	16.5	15.0	17.4	14.6	15.3
SA	21.4	20.9	19.9	19.6	19.2	18.8	17.8	17.9	18.2
No. of Branches	507	516	517	520	528	538	545	545	550
NIM	5.02	5.27	5.62	5.53	5.54	5.52	5.45	5.67	5.04
Yield on Advances	11.46	11.96	12.60	12.80	14.03	14.00	14.12	14.20	13.54
Cost of Deposits	5.19	5.55	5.85	6.15	6.21	6.31	6.39	6.50	6.53
Asset Quality									
GNPA (%)	3.8	3.6	3.4	3.2	3.1	3.1	2.7	2.7	2.9
NNPA (%)	1.3	1.2	1.1	1.0	0.8	0.8	0.7	0.7	0.8
PCR (%)	67.8	68.0	68.1	69.6	75.6	75.1	72.7	73.1	73.0
Slippages (Rs mn)	8,120	6,080	6,810	5,550	5,410	6,660	6,800	7,200	10,260
Slippages - Annualized (%)	5.8	4.2	4.5	3.7	3.4	4.0	3.9	3.9	5.4
CAR (%)	17.4	17.0	17.0	16.7	16.5	15.7	16.2	15.2	15.9
Tier I (%)	15.9	15.5	15.3	15.1	15.2	14.6	14.4	13.8	14.2
ROE Decomposition on total assets (%)									
NII	4.4	4.7	4.8	4.9	4.9	4.9	4.8	5.0	4.6
Other Income (Ex Treasury)	2.0	2.2	2.3	2.2	2.2	2.3	2.5	2.2	2.4
Treasury	0.1	0.1	0.0	0.2	0.1	0.2	0.1	0.1	0.3
Opex	4.6	4.9	5.1	5.0	4.8	5.0	4.8	4.8	4.7
PPOP	1.9	2.1	2.1	2.2	2.4	2.4	2.7	2.5	2.6
Provisioning Cost	0.9	1.1	0.8	0.9	2.1	1.5	1.2	1.1	1.8
РВТ	1.0	1.0	1.3	1.3	0.3	1.0	1.4	1.4	0.8
Tax	0.3	0.2	0.3	0.3	(0.7)	0.2	0.4	0.4	0.2
ROA	0.8	0.8	1.0	1.0	1.0	0.7	1.1	1.1	0.6
ROE	6.2	6.3	8.1	8.4	8.4	6.5	9.7	9.9	5.8

Source: Company, Emkay Research

This report is intended for gauray narkar@emkayolobal.com use and downloaded at 10/21/2024 11:31 AM Emkay Research is also available on www.emkayolobal.com and Bloomberg EMKAY-GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

RBL Bank: Standalone Financials and Valuations

Profit & Loss					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Interest Income	96,764	123,943	144,773	166,394	193,113
Interest Expense	46,784	63,514	76,357	85,341	96,151
Net interest income	49,980	60,429	68,416	81,053	96,961
NII growth (%)	24.1	20.9	13.2	18.5	19.6
Other income	24,823	30,429	37,523	45,756	55,712
Total Income	74,803	90,857	105,939	126,809	152,674
Operating expenses	52,850	60,550	68,177	76,996	87,132
РРОР	21,954	30,307	37,762	49,812	65,541
PPOP growth (%)	(20.0)	38.1	24.6	31.9	31.6
Core PPOP	20,732	28,952	35,459	46,934	62,087
Provisions & contingencies	10,219	17,785	21,649	27,767	32,115
РВТ	11,734	12,522	16,113	22,045	33,426
Extraordinary items	0	0	0	0	0
Tax expense	2,978	844	3,867	5,549	8,413
Minority interest	0	0	0	0	0
Income from JV/Associates	0	0	0	0	0
Reported PAT	8,756	11,679	12,246	16,496	25,013
PAT growth (%)	(1,270.0)	33.4	4.9	34.7	51.6
Adjusted PAT	8,756	11,679	12,246	16,496	25,013
Diluted EPS (Rs)	14.6	19.4	20.2	27.1	41.2
Diluted EPS growth (%)	(1,268.5)	32.8	4.2	34.4	51.6
DPS (Rs)	1.5	2.0	2.5	3.0	3.5
Dividend payout (%)	10.3	10.4	12.4	11.1	8.5
Effective tax rate (%)	25.4	6.7	24.0	25.2	25.2
Net interest margins (%)	4.9	5.2	5.0	5.1	5.2
Cost-income ratio (%)	70.7	66.6	64.4	60.7	57.1
Shares outstanding (mn)	599.6	605.1	607.7	607.7	607.7

Balance Sheet					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Share capital	5,996	6,051	6,077	6,077	6,077
Reserves & surplus	129,770	141,913	153,737	168,410	191,296
Net worth	135,766	147,964	159,814	174,487	197,373
Deposits	848,865	1,034,936	1,233,673	1,481,693	1,798,554
Borrowings	133,313	141,841	145,418	139,197	133,337
Interest bearing liab.	982,178	1,176,777	1,379,091	1,620,890	1,931,892
Other liabilities & prov.	40,818	59,581	51,858	60,302	68,225
Total liabilities & equity	1,158,762	1,384,322	1,590,762	1,855,679	2,197,489
Net advances	702,094	839,869	968,587	1,142,384	1,370,282
Investments	288,754	295,759	348,765	411,353	491,768
Cash, other balances	85,200	144,166	152,171	162,089	173,870
Interest earning assets	1,076,048	1,279,793	1,469,523	1,715,826	2,035,920
Fixed assets	5,740	5,324	6,548	8,010	9,760
Other assets	76,974	99,205	114,691	131,843	151,809
Total assets	1,158,762	1,384,322	1,590,762	1,855,679	2,197,489
BVPS (Rs)	226.4	245.6	263.5	287.1	324.8
Adj. BVPS (INR)	216.8	237.9	254.2	274.7	308.8
Gross advances	718,567	856,379	989,118	1,167,159	1,400,591
Credit to deposit (%)	82.7	81.2	78.5	77.1	76.2
CASA ratio (%)	35.3	37.4	35.2	33.7	33.8
Cost of deposits (%)	4.9	5.7	5.9	5.7	5.4
Loans-to-Assets (%)	60.6	60.7	60.9	61.6	62.4
Net advances growth (%)	17.0	19.6	15.3	17.9	19.9
Deposit growth (%)	7.4	21.9	19.2	20.1	21.4
Book value growth (%)	7.5	8.5	7.3	8.9	13.1

Source: Company, Emkay Research

Y/E Mar

P/E (x)

Source:	Company,	Еткау	Research

Asset quality and other metrics										
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E					
Asset quality										
Gross NPLs	24,198.5	22,709.6	28,125.0	34,894.5	43,298.1					
Net NPLs	7,725.4	6,199.7	7,593.8	10,119.4	12,989.4					
GNPA ratio (%)	3.4	2.7	2.8	3.0	3.1					
NNPA ratio (%)	1.1	0.7	0.8	0.9	0.9					
Provision coverage (%)	68.1	72.7	73.0	71.0	70.0					
Gross slippages	27,547.0	24,413.0	36,102.8	33,847.6	42,017.7					
Gross slippage ratio (%)	3.8	2.9	3.7	2.9	3.0					
LLP ratio (%)	4.6	1.3	2.1	2.5	2.1					
NNPA to networth (%)	6.1	5.5	4.0	4.5	5.5					
Capital adequacy										
Total CAR (%)	16.9	16.2	14.6	13.7	13.0					
Tier-1 (%)	15.3	14.4	13.1	12.3	11.8					
CET-1 (%)	15.3	14.4	13.1	12.3	11.8					
RWA-to-Total Assets (%)	73.5	71.2	74.0	74.0	74.0					
Miscellaneous										
Total income growth (%)	15.6	27.0	18.1	16.4	17.3					
Opex growth (%)	45.9	14.6	12.6	12.9	13.2					
Core PPOP growth (%)	(16.9)	39.7	22.5	32.4	32.3					
PPOP margin (%)	18.1	19.6	20.7	23.5	26.3					
PAT/PPOP (%)	39.9	38.5	32.4	33.1	38.2					
LLP-to-Core PPOP (%)	49.3	61.4	61.1	59.2	51.7					
Yield on advances (%)	11.9	13.1	13.0	12.9	12.7					
Cost of funds (%)	5.0	5.9	6.0	5.7	5.4					

Source: Company, Emkay Research

Valuations and key Ratios FY23 FY24 FY25E FY26E FY27E 14.1 10.6 10.2 7.6 5.0 0.8 0.6 0.8 0.7 0.9

· / = (//)	1.111	1010	1012	710	510
P/B (x)	0.9	0.8	0.8	0.7	0.6
P/ABV (x)	0.9	0.9	0.8	0.7	0.7
P/PPOP (x)	5.6	4.1	3.3	2.5	1.9
Dividend yield (%)	0.7	1.0	1.2	1.5	1.7
DuPont-RoE split (%)					
NII/avg assets	3.9	4.5	4.8	4.6	4.7
Other income	2.2	2.4	2.5	2.7	2.7
Fee income	1.4	1.5	1.6	1.7	1.8
Opex	4.8	4.8	4.6	4.5	4.3
PPOP	2.0	2.4	2.5	2.9	3.2
Core PPOP	1.9	2.3	2.4	2.7	3.1
Provisions	0.9	1.4	1.5	1.6	1.6
Tax expense	0.3	0.1	0.3	0.3	0.4
RoA (%)	0.8	0.9	0.8	1.0	1.2
Leverage ratio (x)	8.2	8.5	9.0	9.7	10.3
RoE (%)	6.7	8.2	8.0	9.9	13.5
Quarterly data					
Rs mn, Y/E Mar	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25
NII	14,750	15,459	15,999	17,000	16,150
NIM (%)	5.5	5.5	5.5	5.7	5.0
PPOP	7,310	7,653	8,870	8,591	9,098
PAT	2,937	2,328	3,526	3,715	2,225
EPS (Rs)	4.90	3.88	5.88	6.19	3.71
. ,					

Source: Company, Emkay Research

This report is intended for gauray narkar@emkayolobal.com use and downloaded at 10/21/2024 11:31 AM Emkay Research is also available on www.emkayolobal.com and Bloomberg EMKAY-GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
07-Oct-24	190	325	Buy	Anand Dama
21-Jul-24	239	350	Buy	Anand Dama
28-Apr-24	264	350	Buy	Anand Dama
21-Jan-24	267	350	Buy	Anand Dama
21-Dec-23	274	350	Buy	Anand Dama
30-Nov-23	233	320	Buy	Anand Dama
26-Oct-23	215	320	Buy	Anand Dama
22-Oct-23	243	320	Buy	Anand Dama
23-Jul-23	219	275	Buy	Anand Dama
23-May-23	145	225	Buy	Anand Dama
01-May-23	160	225	Buy	Anand Dama
09-Mar-23	158	225	Buy	Anand Dama
21-Jan-23	168	225	Buy	Anand Dama
24-Oct-22	126	160	Buy	Anand Dama
22-Aug-22	97	125	Buy	Anand Dama
22-Jul-22	91	125	Buy	Anand Dama
13-Jun-22	87	110	Hold	Anand Dama
13-May-22	109	140	Buy	Anand Dama
28-Jan-22	146	165	Hold	Anand Dama
27-Dec-21	139	165	Hold	Anand Dama
29-Oct-21	178	215	Hold	Anand Dama

RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

Source: Company, Emkay Research

This report is intended for gauray narkar@emkayolobal.com use and downloaded at 10/21/2024 11:31 AM Emkay Research is also available on www.emkayolobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014, EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information. it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

bis report is intended for gauray narkar@emkayolobal.com use and downloaded at 10/21/2024 11:31 AM Emkay Research is also available on www.emkayolobal.com and Bloomberg EMKAYGO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futurez 84t, Chapter 289 of Singapore.

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- EGESL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in 1. the securities recommended in this report as of October 20, 2024
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report 2. Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report З during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities 4. recommended in this report as of October 20, 2024
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the 5. subject company at the end of the month immediately preceding the October 20, 2024
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months. 6.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for
- investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 8. EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	<15% downside

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkavglobal.com

OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.

bis report is intended for gauray narkar@emkayolobal.com use and downloaded at 10/21/2024 11:31 AM Emkay Research is also available on www.emkayolobal.com and Bioomberg EMKAYsGO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore. October 20, 2024 |10